New breast cancer drug: Trastuzumab is officially approved to enter the Chinese market

Fam-trastuzumab deruxtecan-nxki, a revolutionary antibody-conjugated drug, has recently been officially approved by the National Medical Products Administration, marking its official launch in the Chinese market. This brings new hope and vitality to many HER2-positive or low-expression breast cancer patients. The current price of each box of original research drugs on the domestic market is approximately more than RMB 10,000.

The uniqueness of trastuzumab lies in its precise and efficient therapeutic mechanism. By precisely binding to the HER2 receptor on the surface of tumor cells, it can deliver cytotoxic drugs directly to the tumor site to achieve precise strikes, thereby greatly improving the therapeutic effect. In clinical trials, trastuzumab demonstrated excellent performance. Especially in the pivotal trial of DESTINY-Breast03, compared with another breast cancer treatment drug, trastuzumab, detrastuzumab successfully reduced the risk of disease progression or death in patients by 72%. Its emergence not only significantly extends the survival period of patients, but also greatly reduces the risk of disease progression, bringing unprecedented treatment opportunities to breast cancer patients.

Of course, the safety of any drug is uncertain. The safety of trastuzumab has also been fully verified in clinical trials. Although some adverse reactions may occur during use, most of these reactions are within a controllable range, and compared with traditional chemotherapy drugs, the side effects of trastuzumab are significantly smaller. This means that patients’ quality of life can be better protected during treatment.

To sum up, the approval of trastuzumab is undoubtedly a great news for the field of breast cancer treatment in China. Its arrival not only provides a new treatment option for Chinese patients with HER2-positive or low-expression breast cancer, but also marks another solid step in the field of breast cancer treatment in China. We look forward to this drug playing a greater role in future clinical applications and bringing good news to more breast cancer patients.